Emgality vs Aimovig
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Emgality | US Aimovig | |
|---|---|---|
| Generic name | galcanezumab | erenumab |
| Drug class | CGRP Antagonist (Biologic) | CGRP Receptor Antagonist (Biologic) |
| Treats | Migraine prevention, cluster headache | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | Eli Lilly | Amgen/Novartis |
| Year approved | 2018 | 2018 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $110M | $100M |
| Common side effects | Injection site reactions, Constipation, Itching, Allergic reactions | Constipation, Injection site reactions, Muscle cramps, High blood pressure |
Frequently asked questions
Is Emgality or Aimovig better?
Neither is universally "better." Emgality (galcanezumab) and Aimovig (erenumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Emgality and Aimovig?
Emgality is a CGRP Antagonist (Biologic) made by Eli Lilly, while Aimovig is a CGRP Receptor Antagonist (Biologic) made by Amgen/Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Emgality has the larger estimated TV advertising budget of the two.